MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: [Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo].
Author: Ren CX, Chen XX, Zhao L, Tian Y, Xu KL, Zhao K.
Journal: Zhonghua Xue Ye Xue Za Zhi; 2022 Jun 14; 43(6):506-512. PubMed ID: 35968595.
Abstract:
Objective: To optimize the stimulation and activation system of mouse CD3(+) T cells in vitro and explore the optimal infection time of CD3(+) T cells to establish mouse CD19 chimeric antigen receptor T cells (mCD19 CAR-T) , and to also verify its killing effect in vivo and in vitro. Method: Splenic CD3(+)T cells were isolated and purified using magnetic beads, and the cells were cultured in Soluble anti-CD3/CD28, PMA+Ionomycin, and Plated anti-CD3/CD28. Cell activation and apoptosis were assessed by flow cytometry after 8, 24, 48, and 72 hours. ScFv plasmid of mouse CD19 antibody was transfected to plat-E cells to package retrovirus. Activated CD3(+) T cells were infected to construct mouse-specific CD19 chimeric antigen receptor T cells (mCD19 CAR-T) , and mCD19 CAR-T cells were co-cultured with B-cell lymphoma cell line A20 in vitro. The specific toxicity of A20 was detected by flow cytometry, and mCD19 CAR-T cells were infused into the lymphoma mouse model to detect its killing effect and distribution. Results: The activation effect of Plated anti-CD3/CD28 on CD3(+) T cells was superior, with the cells exhibiting good viability 24-48 hours after stimulation. Established mCD19 CAR-T cells with stable efficiency[ (32.27±7.56) % ] were specifically able to kill A20 tumor cells (The apoptosis rate was 24.3% at 48 h) . In vivo detection showed a non-significant decrease in the percentage[ (1.83±0.58) % ] of splenic CD19(+) cells 6 days after mCD19 CAR-T cell infusion. A marked clearance in bone marrow and spleen appeared on day 12 compared with the A20 group, and this difference was statistically significant[spleen: (0.36±0.04) % vs (47.00±13.46) % , P<0.001; bone marrow: (1.82±0.29) % vs (37.30±1.44) % , P<0.0001]. Moreover, mCD19 CAR-T cells were distributed in high proportions in the peripheral blood, spleen, and bone marrow[ (2.90±1.12) % , (4.96±0.80) % , (13.55±1.56) % ]. Conclusion: This study demonstrated an optimized activation system and the optimal infection time of CD3(+) T cells. Furthermore, stable constructed mCD19 CAR-T cells showed a remarkable killing ability in vitro and in vivo. 目的： 优化小鼠CD3(+)T细胞体外刺激活化体系及最佳感染时间，构建小鼠CD19嵌合抗原受体T细胞（mCD19 CAR-T），并验证其在体内外的杀伤效果。 方法： 磁珠分选纯化小鼠的脾脏CD3(+)T细胞，在可溶性抗CD3/CD28抗体、佛波酯+离子霉素、包被抗CD3/CD28抗体3种不同条件下刺激培养，分别于8、24、48和72 h流式细胞术检测细胞活性情况；用包含小鼠CD19抗体的scFv质粒转染Plat-E细胞，包装逆转录病毒后感染活化的CD3(+)T细胞，制备鼠特异性的CD19嵌合抗原受体T细胞（mCD19 CAR-T）。mCD19 CAR-T细胞在体外与B淋巴瘤细胞株A20细胞共培养，利用流式细胞术检测其对A20细胞的靶向杀伤效果；建立淋巴瘤小鼠模型，体内输注mCD19 CAR-T细胞，检测CAR-T细胞的体内杀伤和分布情况。 结果： 包被抗CD3/CD28抗体的刺激活化效果最佳，且在刺激后24～48 h具有较好的细胞活性；抗mCD19的逆转录病毒感染CD3(+) T细胞效率[（32.27±7.56）%]稳定，制备的mCD19 CAR-T细胞可特异性杀伤A20肿瘤细胞，48 h时A20细胞凋亡率为24.3%；体内检测发现输注mCD19 CAR-T细胞第6天即可检测到脾脏中CD19(+)细胞比例[（1.83±0.58）%]显著降低，到建模后第12天骨髓和脾脏中CD19(+)细胞清除更为显著，与A20细胞组相比差异具有统计学意义[脾脏：（0.36±0.04）%对（47.00±13.46）%，P<0.001；骨髓：（1.82±0.29）%对（37.30±1.44）%，P<0.0001]。且mCD19 CAR-T细胞在外周血、脾脏和骨髓中均有分布，GFP(+)CD3(+) CAR-T细胞比例分别为（2.90±1.12）%、（4.96±0.80）%、（13.55±1.56）%，以骨髓中占比最高。 结论： 获得优化的CD3(+) T细胞活化刺激体系和最佳感染时间，稳定构建了抗mCD19 CAR-T细胞，并在体内外验证其具备良好的杀伤能力。.

[Abstract] [Full Text] [Related] [New Search]